ACE2 News and Research

RSS

Microbiota-derived molecules do not change the entry or replication of SARS-CoV-2 in intestinal cells

A study conducted at the University of Campinas in the state of São Paulo, Brazil, shows that compounds produced by gut microbiota (bacteria and other microorganisms) during fermentation of insoluble fiber from dietary plant matter do not affect the ability of the novel coronavirus SARS-CoV-2 to enter and replicate in cells lining the intestines.

30 Mar 2021

Researchers develop novel test that screens for SARS-CoV-2 variants of concern

A team of scientists from the United States has recently developed a single-tube duplex molecular assay for rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants containing E484K and N501Y spike mutations.

30 Mar 2021

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

In the continued need for next-generation vaccines that confer broad protection against COVID-19, scientists developed an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine.

30 Mar 2021

Using ACE2 structure to predict SARS-CoV-2 susceptibility in animals

Researchers based at the Rice University, Texas, USA, have now demonstrated a novel method of predicting a species' susceptibility to contracting COVID-19, based on the animal's structure of ACE2.

30 Mar 2021

Vaccine-induced 2C08 antibody protects against SARS-CoV-2 variants

A new preprint study posted to the bioRxiv* server led by Ali H. Ellebedy from the Washington University School of Medicine found that the monoclonal antibody 2C08 produced by the Pfizer vaccine could help neutralize COVID-19 variants.

29 Mar 2021

Have scientists found SARS-CoV-2's Achilles' heel?

Have scientists uncovered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Achille's heel? New preclinical research from Cell neutralizing antibodies targeting the N-terminal domain of the coronavirus could be a potential target for antibodies to bind and effectively neutralize SARS-CoV-2.

29 Mar 2021

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Researchers at the Institute of Medical Virology, the University of Zurich in Switzerland, have identified features in the SARS-CoV-2 genome that are important for human respiratory cell growth.

29 Mar 2021

Addressing the increasing plasticity of SARS-CoV-2

Researchers summarize what this rapid increase of plasticity of SARS-CoV-2 could mean for the future of the pandemic and anti-SARS-CoV-2 measures.

29 Mar 2021

Virus-cell interaction may partly explain the higher infection rate of COVID-19

Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.

29 Mar 2021

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.

28 Mar 2021

New SARS-CoV-2 genome variants identified in US mink

Researchers in Canada have discovered two novel variants in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gene sequences collected from mink in the United States.

28 Mar 2021

mRNA vaccines and monoclonal antibodies protect against new NYC-B.1.526 variant

A new fast-spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526 recently emerged in New York City and caused concerns for its potential to resist the immune system.

28 Mar 2021

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.

28 Mar 2021

Novel molecule could offer a new way to fight against SARS coronavirus 2

Scientists at the University of Bonn and the caesar research center have isolated a molecule that might open new avenues in the fight against SARS coronavirus 2. The active ingredient binds to the spike protein that the virus uses to dock to the cells it infects.

27 Mar 2021

Scientists reveal salivary gland cells as sites of COVID-19 infection

Scientists have shown that SARS-CoV-2, the virus that causes COVID-19, can infect specific cells in the salivary gland in the mouth.

25 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Researchers find evidence that SARS-CoV-2 infects cells in the mouth

An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth.

25 Mar 2021

Alzheimer’s symptoms linked to COVID-induced brain injury

New research shows further evidence between COVID-19 infection and the development of long-term neurological symptoms. The findings found COVID-induced neuroinflammation and microvascular injury contributed to dementia-like symptoms. However, they also found evidence indicating a low possibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly invading the brain.

24 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

A recent study from France showed that the UK variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – also known as B.1.1.7 variant – can replicate much more efficiently in a reconstituted human bronchial epithelium, which may explain why it spreads so rapidly in the human population. The study is currently freely available on the bioRxiv preprint server.

24 Mar 2021